|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
|
|---|---|---|---|---|
| Assets | ||||
| Deferred offering costs | ||||
| Current assets | ||||
| Cash | ||||
| Prepaid expenses and other current assets | ||||
| Total Current assets | ||||
| Long-term prepaid insurance | ||||
| Cash held in Trust Account | ||||
| TOTAL ASSETS | ||||
| Liabilities and Shareholders' Deficit | ||||
| Current liabilities | ||||
| Accrued offering costs | ||||
| Accounts payable and accrued expenses | ||||
| Promissory note - related party | ||||
| Due to related party | ||||
| Accrued expenses | ||||
| Total Current liabilities | ||||
| Deferred underwriting fee payable | ||||
| TOTAL LIABILITIES | ||||
| Class A Ordinary Shares subject to possible redemption, 15,300,000 shares at redemption value of $10.25 and $10.15 per share at March 31, 2025 and December 31, 2024, respectively | ||||
| SHAREHOLDERS' DEFICIT | ||||
| Ordinary shares | ||||
| Additional paid-in capital | ||||
| Accumulated deficit | ||||
| TOTAL SHAREHOLDERS' DEFICIT | ||||
| TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT |
Loading...
